Conference Coverage

Atrial fibrillation boosts VTE risk



– Atrial fibrillation is at least as strong a risk factor for venous thromboembolism as for ischemic stroke, Bjorn Hornestam, MD, asserted at the annual congress of the European Society of Cardiology.

This novel finding from a Swedish national registry study suggests it’s time for thoughtful consideration of a revision of risk scores in patients with atrial fibrillation (AF), according to Dr. Hornestam, director of cardiology at Sahlgrenska University Hospital in Gothenburg, Sweden.

“VTE risk is not included as an outcome in the CHA2DS2-VASc score, so we underestimate the total thromboembolic risk in AF patients,” he said.

Dr. Hornestam presented a Swedish registry study of 1.36 million patients, including 470,738 patients with new-onset AF and no previous diagnosis of VTE or ischemic stroke and twice as many controls without AF who were matched to the AF patients by age, gender, and county.

Dr. Bjorn Hornestam, director of cardiology at Sahlgrenska University Hospital in Gothenburg, Sweden

Dr. Bjorn Hornestam

The VTE risk was highest during the first 30 days after diagnosis of AF. Women with new-onset AF had an 8.3-fold increased risk of VTE compared with controls during this early period, by a margin of 55.8 versus 6.4 cases per 1,000 person-years. Men with newly diagnosed AF had a 7.2-fold increased risk of VTE in the first 30 days, reflecting a rate of 40.1 per 1,000 person-years compared to 5.6 per 1,000 in controls.

The VTE risk dropped off precipitously in men after the first month. The rate was cut in half by 2 months after AF diagnosis and was no different from that of controls by 9 months.

In women, too, the early elevated VTE risk was halved by 2 months out, but thereafter the rate of decline in VTE risk slowed. Even 10 years after AF diagnosis, women had a 21% greater VTE risk than did matched controls.

Of note, the risk of VTE during the first 12 months after diagnosis of AF was nearly twice as great in both men and women under age 65 than in those older than 75.

These data raise the question of whether standard therapy in AF patients needs to be modified, especially during what now appears to be the critical time frame of the first 3-6 months after diagnosis of the arrhythmia, Dr. Hornestam said.

He reported having no financial conflicts of interest regarding this study.

Recommended Reading

New-onset AF boosts bad HFrEF outcomes
The Hospitalist
CRT-D beneficial in mild HF with ejection fraction above 30%
The Hospitalist
PPIs triple heart failure hospitalization risk in atrial fib patients
The Hospitalist
Amplatzer devices outperform oral anticoagulation in atrial fib
The Hospitalist
New findings from first all-female TAVR registry
The Hospitalist
Despite global decline, rheumatic heart disease persists in poorest regions
The Hospitalist
Undiagnosed AF common in higher-risk patients
The Hospitalist
VIDEO: Educational intervention boosts A fib anticoagulation
The Hospitalist
Dabigatran, rivaroxaban linked to slight increase in GI bleeding risk
The Hospitalist
Oral anticoagulation ‘reasonable’ in advanced kidney disease with A-fib
The Hospitalist
   Comments ()